NCT05926414View on ClinicalTrials.gov

To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus

Active, not recruitingOBSERVATIONAL
Enrollment

15,000

Participants

Timeline

Start Date

September 21, 2023

Primary Completion Date

January 17, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Enavogliflozin

treated with Envlo tab. 0.3mg

DRUG

Enavogliflozin

Envlomet SR Tablet 0.3/1,000mg

Trial Locations (1)

Unknown

NaRi Kim, Seoul

Sponsors
All Listed Sponsors
lead

Daewoong Pharmaceutical Co. LTD.

INDUSTRY